Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Zoccoli-Rodriguez

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 3, 2025
Restriction of IgA secretion in gut plasma cells is driven by a tissue-specific glycolytic programVictoria Zoccoli-Rodriguez, John D Iwaniec, Joel R Wilmore
Inflammatory Bowel Diseases|May 3, 2018
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic MechanismsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2019
Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the GutAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T CellsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Frontiers in Immunology|March 15, 2018
NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel DiseaseAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Scientific Reports|June 28, 2020
Abscisic acid enriched fig extract promotes insulin sensitivity by decreasing systemic inflammation and activating LANCL2 in skeletal muscleAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
International Journal of Toxicology|February 23, 2019
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Artificial Intelligence in Medicine|August 3, 2017
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infectionAndrew Leber, Raquel Hontecillas, Vida Abedi, et al.
Research Square|May 27, 2024
Gut commensals require Peyer's patches to induce protective systemic IgA responsesJoshua R Harris, Victoria Zoccoli-Rodriguez, Mara S Delaney, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|December 3, 2025
Restriction of IgA secretion in gut plasma cells is driven by a tissue-specific glycolytic programVictoria Zoccoli-Rodriguez, John D Iwaniec, Joel R Wilmore
Inflammatory Bowel Diseases|May 3, 2018
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic MechanismsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2019
Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the GutAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T CellsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Frontiers in Immunology|March 15, 2018
NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel DiseaseAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Scientific Reports|June 28, 2020
Abscisic acid enriched fig extract promotes insulin sensitivity by decreasing systemic inflammation and activating LANCL2 in skeletal muscleAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
International Journal of Toxicology|February 23, 2019
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Artificial Intelligence in Medicine|August 3, 2017
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infectionAndrew Leber, Raquel Hontecillas, Vida Abedi, et al.
Research Square|May 27, 2024
Gut commensals require Peyer's patches to induce protective systemic IgA responsesJoshua R Harris, Victoria Zoccoli-Rodriguez, Mara S Delaney, et al.
Pageof 2